Vericel posted 2Q17 orthobiologic revenue of US $12.9MM, +43.4% vs. 2Q16, and 1H17 revenue of $17.9MM, +27.9% vs. 1H16.
2Q17
2Q16
$ Change
% Change
Orthobiologics
$12.9
$9.0
$3.9
43.4%
1H17
1H16
$ Change
% Change
Orthobiologics
$17.9
$14.0
$3.9
27.9%
Performance highlights:
Last quarter that revenue will include both Carticel (autologous cultured chondrocytes) and MACI (autologous cultured chondrocytes on porcine collagen membrane); Carticel no longer commercially available
Carticel represented 15% of 2Q orders
Noted resolution of dispute between Vital Care (a contracted pharmacy service provider) and a payor, which resulted in recognition of additional $1.4MM in MACI revenue
>350 surgeons trained on MACI since 1Q launch; 50% of trained surgeons are former Carticel users or never used Carticel
Entered distribution agreement with Orsini Healthcare to support MACI patient access/case management
Entered into a license agreement for Innovative Cellular Therapeutics to exclusively develop and distribute products in Asia
Payor policies updated at 18 of top 28 commercial plans, representing ~1/2 of covered lives
Vericel posted 2Q17 orthobiologic revenue of US $12.9MM, +43.4% vs. 2Q16, and 1H17 revenue of $17.9MM, +27.9% vs. 1H16.
Q17 2Q16 $ Change % Change
Orthobiologics $12.9 $9.0 $3.9 ...
Vericel posted 2Q17 orthobiologic revenue of US $12.9MM, +43.4% vs. 2Q16, and 1H17 revenue of $17.9MM, +27.9% vs. 1H16.
2Q17
2Q16
$ Change
% Change
Orthobiologics
$12.9
$9.0
$3.9
43.4%
1H17
1H16
$ Change
% Change
Orthobiologics
$17.9
$14.0
$3.9
27.9%
Performance highlights:
Last quarter that revenue will include both Carticel (autologous cultured chondrocytes) and MACI (autologous cultured chondrocytes on porcine collagen membrane); Carticel no longer commercially available
Carticel represented 15% of 2Q orders
Noted resolution of dispute between Vital Care (a contracted pharmacy service provider) and a payor, which resulted in recognition of additional $1.4MM in MACI revenue
>350 surgeons trained on MACI since 1Q launch; 50% of trained surgeons are former Carticel users or never used Carticel
Entered distribution agreement with Orsini Healthcare to support MACI patient access/case management
Entered into a license agreement for Innovative Cellular Therapeutics to exclusively develop and distribute products in Asia
Payor policies updated at 18 of top 28 commercial plans, representing ~1/2 of covered lives
Copy to clipboard 
